<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="363">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102138</url>
  </required_header>
  <id_info>
    <org_study_id>B4711005</org_study_id>
    <secondary_id>2015-002267-42</secondary_id>
    <nct_id>NCT03102138</nct_id>
  </id_info>
  <brief_title>Retinal Pigment Epithelium Safety Study For Patients In B4711001</brief_title>
  <official_title>Long Term, Open-label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a
      further 4 years with regular visits to assess safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>incidence of serious adverse events and ocular adverse events</measure>
    <time_frame>4 years</time_frame>
    <description>incidence of serious adverse events and ocular adverse events will be monitored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (pre-implantation) in ETDRS (Early Treatment of Diabetic Retinopathy Study) best corrected visual acuity (BCVA)</measure>
    <time_frame>4 years</time_frame>
    <description>Change from baseline (pre-implantation) in ETDRS (Early Treatment of Diabetic Retinopathy Study) best corrected visual acuity (BCVA). The Proportion of subjects with an improvement of 15 letters or more at all timepoints will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ETDRS BCVA and change from baseline (pre-implantation) at all timepoints.</measure>
    <time_frame>4 years</time_frame>
    <description>Mean ETDRS BCVA and change from baseline (pre-implantation) at all timepoints will be assessed</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study.

          -  Previous participation in Protocol B4711001 and received treatment with PF-05206388.

          -  Subjects who are willing and able to comply with scheduled visits, and study
             procedures.

        Exclusion Criteria:

          -  there are no exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4711005&amp;StudyName=Long%20Term%2C%20Open-label%2C%20Safety%20Follow%20Up%20Study%20Following%20Transplantation%20Of%20Pf-05206388%20%28human%20Embryonic%20Stem%20Cell%20Derived%20Retinal%20Pigment%20Epithelium%20%28rpe%29%29%20In%20Subjects%20With%20Acute%20Wet%20Age%20Related%20Macular%20Degeneration%20And%20Recent%20Rapid%20Vision%20Decline</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4711005&amp;StudyName=Long+Term%2C+Open-label%2C+Safety+Follow+Up+Study+Following+Transplantation+Of+Pf-05206388+%28human+Embryonic+Stem+Cell+Derived+Retinal+Pigment+Epithelium+%28rpe%29%29+In+Subjects+With+Acute+Wet+Age+Related+Macular+Degeneration+And+Recent+Rapid+Vision+Decline</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
